Shilpa Medicare has received USFDA approval of Azacitidine injection which is used in the treatment of myelodysplastic syndrome. Myelodysplastic syndrome is a condition that affects the bone marrow and the blood cells it produces. In July this year, Shilpa Medicare had completed USFDA inspection formalities for its Jadcherla formulations facility near Hyderabad without any critical observations.
Company Profile : Shilpa Medicare Ltd
Leave a Reply